Colorectal cancer is the fourth most common cancer in the U.S. and the second deadliest. With colon cancer, some earlier stage patients fare worse than some later stage patients, who usually benefit most from chemotherapy. But a research team at Mayo Clinic has discovered that a simple blood test could help determine which patients are at a higher risk and therefore could benefit from therapy.
The researchers also found many patients who could benefit from the test likely aren’t receiving it.
The team of physicians and scientists, using data from the National Cancer Database for 40,844 patients, looked at a blood test that measures the protein called carcinoembryonic antigen, or CEA. Carcinoembryonic antigen can be found in higher levels in people with certain cancers, especially colon cancer.
The findings, published in the Journal of Gastrointestinal Surgery, showed that knowing these blood test results prior to treatment could have changed the classification from average to high risk for more than 1 in 6 stage 2 colon cancer patients. That change could have altered treatment options, including whether to use chemotherapy.
“The decision to give a patient chemotherapy after surgery is not a light one, and physicians must weigh the risks and benefits,” says senior author Kellie Mathis, M.D., a Mayo Clinic colon and rectal surgeon. “We are currently using the blood test to help make these difficult decisions, and we suggest other physicians do the same.”
The blood test has been around for decades but is not broadly used across the country. It was recorded in 54 percent of cases meeting other relevant criteria for the study. While in some cases the test may not have been entered in the database, many other patients may not be getting it.
“There is no good reason for a physician to omit this blood test, and more work needs to be done to ensure that all patients receive it,” Dr. Mathis says.
When patients get the blood test, the authors point out it is often done after surgery to monitor the cancer’s development. Greater, and earlier, consideration of protein level may be warranted, the researchers say.
The researchers also discovered that, for stage 2 patients who had surgery but not chemotherapy, the five-year survival rate was 66 percent for those with elevated protein levels and 76 percent for those without elevated levels. And for patients with elevated protein levels, those who had chemotherapy and surgery fared better than those who only had surgery.
“If a patient with a new diagnosis of stage 2 colon cancer has an elevated carcinoembryonic antigen level, physicians should consider chemotherapy in addition to surgery,” says Dr. Mathis.
There are four primary stages of colon cancer. Generally, with stage 2, the cancer hasn’t spread to nearby lymph nodes or distant organs but has grown into or through the wall of the colon.
To perform the patient-centered research, physicians in the Mayo Clinic Division of Colon and Rectal Surgery collaborated with scientists in the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.
The lead author is Blake Spindler, M.D., a resident in the Mayo Clinic School of Graduate Medical Education. The other authors are John Bergquist, M.D., and Cornelius Thiels, D.O., both residents in the Mayo Clinic School of Graduate Medical Education, and Elizabeth Habermann, Ph.D., Scott Kelley, M.D., and David W. Larson, M.D., all from Mayo Clinic.
The study was funded by the Mayo Clinic Department of Surgery, the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery and the Mayo Clinic Clinician-Investigator Training Program.
Tags: blood test, cancer, cancer staging, carcinoembryonic antigen, CEA, chemotherapy, colon cancer, Dr. Blake Spindler, Dr. David Larson, Dr. Elizabeth Habermann, Dr. Kellie Mathis, Findings, Kern Center, Mayo Clinic Kern Center for the Science of Health Care Delivery, Mayo Clinic research, Mayo Clinic School of Graduate Medical Education, medical research, research, Science of health care delivery